Physician profile
Michael J Rymar
NPI 1700998549
$1,610.67
in general payments reported to CMS, 2019-2025
16 companies · $702 in 2025
The $702 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $91.80 · 2022: $124 · 2023: $165 · 2024: $402 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $414.20 | 2024-2025 | Rocklatan, Precision7, Total30 |
| Biotissue Holdings INC. | $269.54 | 2019-2025 | |
| Abbvie INC. | $203.88 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Allergan, INC. | $122.57 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $88.79 | 2024-2025 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $72.24 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $60.65 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $58.36 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $54.57 | 2023 | Infuse, Biotrue, Vyzulta |
| Dompe US, INC. | $53.28 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $44.56 | 2023-2024 | Syfovre |
| Oyster Point Pharma, INC. | $39.85 | 2023-2024 | Tyrvaya |
| Astellas Pharma US INC | $36.72 | 2024 | Izervay |
| Coopervision INC. | $35.11 | 2019-2024 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $34.77 | 2023-2025 | Acuvue |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $21.58 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rymar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.